ClinicalTrials.gg
TerminatedNCT06003608SmIleUpdated Oct 20, 2026

Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

An observational study in Parkinson Disease, sponsored by Nimble Science Ltd.. Terminated at 1 site in Canada. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Nimble Science Ltd. · Observational

How we know

Why this study was terminated
Study recruitment phase exceeded the time allotted
Updated Oct 20, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
51
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Enrollment
33rd of 41
51 · median 315
Started
2024
with 10 others
Observational
41 of 253
12 open now
Registered
217th of 253
by date

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 33rd largest by enrollment of the 41 observational ones that give a count, is one of 11 that started in 2024, is one of 41 observational ones, and was the 217th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally and recovered together with the stools (home recovery) together with blood sampling (during the onsite visit).

Read the detailed description

Participants will be swallowing two SIMBA capsules which allows for minimally-invasive sampling of the microbiome and metabolome deep in the small intestine. Researchers will use the capsule samples to determine the small intestinal microbiome and metabolomic signatures in luminal fluid samples from the small bowel in Parkinson Disease (PD) patients compared to healthy controls (HC).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Eligibility will be determined based on information reported by the subject and the results of the screening assessments (physical exam, etc). Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:

  1. Males and females aged 50-85 years old at time of on-site visit
  2. Signed
  3. Willing \& able to comply with study procedures (including SIMBA capsule ingestion) and have study assessments performed
  4. Able to swallow a size-00 capsule (23mm length) in OFF state Additional inclusion criteria for PD patients only
  5. Diagnosis of idiopathic PD (Clinically Probable PD), including documented levodopa responsiveness
  6. Treatment with an immediate release levodopa formulation during the day at a stable dose for at least 2 months prior to enrollment

Exclusion criteria

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

  1. Any risk of capsule non-excretion, including, e.g., prior gastrointestinal disease, surgery, or radiation treatment which, in the Investigator's opinion, would lead to intestinal structuring or obstruction, achalasia, eosinophilic esophagitis, any inflammatory bowel disease (IBD), cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery; appendectomy or cholecystectomy more than 3 months prior to on-site study visit are acceptable,
  2. Use of any medications in the week prior to the on-site study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics); laxative use is allowed provided that it is kept unchanged in the week prior to the study visit. PPIs are allowed provided a of 48 hours is respected before swallowing the SIMBA capsules and PPI treatment is resumed only 4 hours thereafter,
  3. Any for using domperidone, including a long , concomitant use of QT prolonging drugs, any risk of significant electrolyte abnormality, known , known liver impairment or significant (e.g. unstable) cardiac disease (see label) putting the subject at significant risk according to the investigator's clinical judgement
  4. History of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration, e.g. SDQ score > 4,
  5. Any concomitant PD treatment, including any dopamine agonist and MAO-B inhibitor, except (for PD patients only) an immediate release levodopa formulation during the day (required per inclusion criterion), the concomitant use of a decarboxylase inhibitor and the use of a controlled release levodopa formulation at bedtime,
  6. Major genital and/or rectum prolapse,
  7. Any concomitant or previous treatment (\<2 months from on-site study visit) with significant anti-inflammatory or immune suppressant medication, e.g. DMARDs, biologicals or systemic , except non-chronic PRN use of an NSAID and/or 5-ASA (mesalazine) treatment,
  8. Active cancer, including any prolactinoma, within 5 years (allowed: uncomplicated basal cell carcinoma and successfully removed carcinoma in situ),
  9. immune deficiency (according to Investigator's judgement),
  10. Documented infection, or any clinically significant systemic infection,
  11. Antibiotic use (except for local use), use of prebiotics, or probiotics ≤12 weeks prior to on-site study visit, or Fecal Microbiota Transplantation anytime in medical history
  12. Dementia in medical history or identified by a \<24,
  13. Insulin-dependent diabetes mellitus,
  14. Current Psychosis episode by clinical judgement based on anamnesis
  15. Active significant impulse control disorder (by clinical judgement and based on interview and medical records)
  16. Pregnancy
  17. Alcohol or drug abuse
  18. Deep brain stimulation or Duodopa/Lecigon treatment.
  19. Subject, according to investigator assessment, not expected to be able to comply with study procedures including SIMBA capsule recovery and SIBO breath test execution with - or without help (when home).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
51 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy control (HC)

    25 neurotypical controls, age-matched to the Parkinson's disease group

    Device: Fluid biopsy capsule

  • Parkinson's disease (PD)

    75 Parkinson's disease patients

    Device: Fluid biopsy capsule · Drug: Levodopa-Carbidopa Immediate Release

Interventions

  • DeviceFluid biopsy capsule

    Ingestion of two SIMBA capsules

  • DrugLevodopa-Carbidopa Immediate Release

    Single dose, Levodopa-Carbidopa Immediate Release

06

What researchers measure

Primary outcomes

  1. Difference in microbiome profile of small intestine samples between groups

    Functional dysbiosis profile of the small intestinal microbiota of Parkinson's Disease patients compared to age-matched neurotypical controls, as determined by whole metagenome shotgun sequencing based profiling

    Time frame: Baseline

Secondary outcomes

  1. Difference in blood metabolome composition between groups

    Blood metabolome composition profile of Parkinson's Disease patients as compared to age-matched neurotypical controls, as determined by metabolomics analysis

    Time frame: Baseline

  2. Correlation between the observed small intestine microbiome profile and blood metabolome composition, including, in PD subjects, levodopa pharmacodynamics

    Small intestinal and blood pharmacodynamics of Levodopa as a function of small intestinal microbiota profiles, as determined by blood and small intestinal metabolomics and small intestinal whole metagenome shotgun profiling and appropriate statistical correlation methods

    Time frame: Baseline

07

Study locations

1 site
  • University of Calgary
    Calgary, Alberta T2N 1N4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2024 to primary completion in Jan 2025, 10 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Feb 2025 → Jan 2025 and completion Feb 2025 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Aug 22, 2023
StartActual
Feb 19, 2024
Primary completionActual
Jan 1, 2025was Feb 2025
CompletionActual
Jan 1, 2025was Feb 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Study recruitment phase exceeded the time allotted
changed Oct 20, 2026
Primary completion
Feb 2025→Jan 1, 2025 (actual)
Oct 20, 2026
Study completion
Feb 2025→Jan 1, 2025 (actual)
Oct 20, 2026
Enrollment
100 (estimated)→51 (actual)
Oct 20, 2026
Sponsor
Collaborators added: MRM Health NV; collaborators removed: MRM Health N.V.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Terminated
    Why stopped Study recruitment phase exceeded the time allotted
    Primary completion Feb 2025→Jan 1, 2025 (now actual)
    Study completion Feb 2025→Jan 1, 2025 (now actual)
    Enrollment 100 (estimated)→51 (actual)
    Sponsor Collaborators added: MRM Health NV; collaborators removed: MRM Health N.V.
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06003608
Lead sponsor
Nimble Science Ltd.
Collaborators
MRM Health NV
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Feb 19, 2024
Primary completion
Jan 1, 2025
Completion
Jan 1, 2025
Last update
Oct 20, 2026

Study contacts

Davide Martino, MD PHD
principal investigator · University of Calgary

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion